Literature DB >> 18071675

Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers.

Wojciech Krzyzanski1, Elzbieta Wyska.   

Abstract

The purpose of this study was to apply the target-mediated drug disposition (TMDD) pharmacokinetic (PK) model to describe binding, internalization, and turnover of erythropoietin receptor (EPOR). This model allows one to determine from free drug (C) PK data not only parameters describing linear disposition of EPO such as the elimination rate constant (kel) and volume of distribution (Vc), but also the total receptor concentration (Rtot0), drug-receptor complex (RC) internalization rate constant (kint), as well as synthesis and degradation rate constants (ksyn and kdeg) for the receptor turnover. The previously published data on PK of recombinant EPO (rHuEPO) in humans and the results of EPOR binding studies were used for analysis. The estimated PK parameters were used to simulate time courses of free and bound EPOR after IV administration of clinically relevant rHuEPO doses. The estimates of kel=0.106 h(-1) and Vc=0.032 l/kg are consistent with reported in the literature values of rHuEPO linear disposition parameters. The determined value of Rtot0 was 66.35 pM and the half-life for EPOR degradation was 8.8 h. Computer simulations showed a very rapid binding phase in the EPOR time profile followed by a decline to a nadir, and a subsequent return to the baseline. The nadir values decreased with increasing doses and resulted in the maximum values of the bound fractions of the total EPOR in the ranges 33-99%. At the baseline conditions, only 3.1% of EPOR were occupied. The saturation of EPOR was correlated with the time C remained above the KD level. In conclusion, the time courses of serum rHuEPO concentrations contain information about internalization and turnover of EPOR. Kinetics of EPOR can be utilized to determine the relationship between the pharmacologic effect and exposure to rHuEPO.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18071675     DOI: 10.1007/s00210-007-0225-z

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  28 in total

1.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

Review 2.  Erythropoietin: structure, control of production, and function.

Authors:  W Jelkmann
Journal:  Physiol Rev       Date:  1992-04       Impact factor: 37.312

3.  Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa.

Authors:  John Glaspy; David Henry; Ravi Patel; Simon Tchekmedyian; Steve Applebaum; Donald Berdeaux; Richard Lloyd; Russell Berg; Matt Austin; Greg Rossi
Journal:  Eur J Cancer       Date:  2005-04-08       Impact factor: 9.162

4.  Circadian rhythm of serum erythropoietin in healthy subjects.

Authors:  P Pasqualetti; R Casale
Journal:  Riv Eur Sci Med Farmacol       Date:  1996 May-Jun

Review 5.  Pharmacologic target-mediated drug disposition.

Authors:  G Levy
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

6.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.

Authors:  Wojciech Krzyzanski; William J Jusko; Mary C Wacholtz; Neil Minton; Wing K Cheung
Journal:  Eur J Pharm Sci       Date:  2005-11       Impact factor: 4.384

Review 7.  Biology of erythropoietin.

Authors:  C Lacombe; P Mayeux
Journal:  Haematologica       Date:  1998-08       Impact factor: 9.941

8.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.

Authors:  Rohini Ramakrishnan; Wing K Cheung; Mary C Wacholtz; Neil Minton; William J Jusko
Journal:  J Clin Pharmacol       Date:  2004-09       Impact factor: 3.126

9.  Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta.

Authors:  C E Halstenson; M Macres; S A Katz; J R Schnieders; M Watanabe; J T Sobota; P A Abraham
Journal:  Clin Pharmacol Ther       Date:  1991-12       Impact factor: 6.875

Review 10.  Erythropoietin: physiology and pharmacology update.

Authors:  James W Fisher
Journal:  Exp Biol Med (Maywood)       Date:  2003-01
View more
  13 in total

1.  Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.

Authors:  A Dubois; S Gsteiger; S Balser; E Pigeolet; J L Steimer; G Pillai; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

Review 2.  The receptor that tames the innate immune response.

Authors:  Michael Brines; Anthony Cerami
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

3.  Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.

Authors:  Mohammad I Saleh; John A Widness; Peter Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2011-01-10       Impact factor: 1.627

4.  Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations.

Authors:  Pawel Wiczling; Philip Lowe; Etienne Pigeolet; Frank Lüdicke; Sigrid Balser; Wojciech Krzyzanski
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  A Mass Balance-Based Semiparametric Approach to Evaluate Neonatal Erythropoiesis.

Authors:  Denison J Kuruvilla; John A Widness; Demet Nalbant; Robert L Schmidt; Donald M Mock; Peter Veng-Pedersen
Journal:  AAPS J       Date:  2015-10-26       Impact factor: 4.009

6.  Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.

Authors:  Lambertus A Peletier; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-01       Impact factor: 2.745

7.  rhErythropoietin-b as a tissue protective agent in kidney transplantation: a pilot randomized controlled trial.

Authors:  Beatrice Coupes; Declan G de Freitas; Stephen A Roberts; Ian Read; Hany Riad; Paul E C Brenchley; Michael L Picton
Journal:  BMC Res Notes       Date:  2015-02-03

8.  A biomathematical model of human erythropoiesis under erythropoietin and chemotherapy administration.

Authors:  Sibylle Schirm; Christoph Engel; Markus Loeffler; Markus Scholz
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

9.  A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.

Authors:  P Dua; E Hawkins; P H van der Graaf
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-15

10.  A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment.

Authors:  Sibylle Schirm; Christoph Engel; Markus Loeffler; Markus Scholz
Journal:  Theor Biol Med Model       Date:  2014-05-26       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.